Olema Oncology expands collaboration agreement with Novartis

Olema Pharmaceuticals (OLMA) announced an amendment to the existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. (NVS) to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients. Olema first signed a clinical collaboration and supply agreement with Novartis in July 2020, the agreement was amended and restated in January 2022, and focuses on the evaluation of the safety, tolerability and efficacy of palazestrant in combination with Novartis’ proprietary cyclin-dependent kinase 4 and 6 inhibitor ribociclib and/or Novartis’ proprietary phosphatidylinositol 3-kinase inhibitor alpelisib in patients with metastatic ER+ breast cancer. The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.